<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02302209</url>
  </required_header>
  <id_info>
    <org_study_id>10-04286</org_study_id>
    <nct_id>NCT02302209</nct_id>
  </id_info>
  <brief_title>Dyad Oxytocin Study (DOS)</brief_title>
  <acronym>DOS</acronym>
  <official_title>Effects of Oxytocin on Familial Interactions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      The purpose of the investigators proposed study is twofold: 1) To investigate the role of the
      affiliative neuropeptide oxytocin in unhealthy interactions in families of patients with
      schizophrenia and families of patients with autism spectrum disorder, and 2) to investigate
      whether manipulation of this oxytocinergic system positively influences these family
      interactions.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Negative Expressed Emotion</measure>
    <time_frame>Continuously for 4 hours after drug adimistration</time_frame>
    <description>We will measure the number of times caregivers show parental criticism, hostility, lack of warmth and emotional over-involvement.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 IU Oxytocin Intranasal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline Nasal Spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <arm_group_label>Oxytocin</arm_group_label>
    <other_name>Syntocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion criteria for caregiver of patients with schizophrenia, patients with autism
             spectrum disorder, and healthy controls:

          -  Age between 18 and 75 years old

          -  Must have at least 4 hours of contact with the patient per week and be considered a
             &quot;significant caregiver&quot; by the patient

        Inclusion criteria for patients with schizophrenia:

          -  Between the ages of 14 and 45.

          -  Patients must have a diagnosis of schizophrenia, schizophreniform disorder,
             schizoaffective disorder or psychosis- Not Otherwise Specified (NOS).

          -  Patients must be clinically stable

          -  No or minor changes to medications in the past week

          -  Patients must have a primary caregiver

          -  Inclusion criteria for healthy control child:

          -  Between the ages of 14 and 45

          -  Healthy control must have a primary caregiver

          -  Inclusion criteria for patients with autism spectrum disorder

          -  Between the ages of 14 and 45

          -  Patient must have a primary caregiver

          -  Patients must have a diagnosis of an autism spectrum disorder (ASD) (autism or
             Asperger's disorder), pervasive developmental disorder (PDD) or pervasive
             developmental disorder - not otherwise specified (PDD-NOS).

        Exclusion Criteria:

        Exclusion criteria for all caregivers:

          -  Female caregivers that state that they are pregnant or have a positive urine pregnancy
             test

          -  Caregivers who have significant nasal pathology, atrophic rhinitis, recurrent nose
             bleeds, or history of cranial-surgical procedures (hypophysectomy)

          -  Caregivers with significant psychiatric, neurologic, or medical illness

          -  Exclusion criteria for healthy controls:

          -  Healthy controls with history of psychiatric or neurological illness

          -  Exclusion criteria for patients with an autism spectrum disorder:

          -  Patients with an Intelligence Quotient (IQ) lower than 75

          -  Exclusion criteria for patients with schizophrenia

          -  Patients with severe brain trauma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josh D Woolley, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC San Francisco and SFVAMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Lin, BS</last_name>
    <phone>415-881-7037</phone>
    <phone_ext>4117</phone_ext>
    <email>Bandlab@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Win Huynh, BS</last_name>
    <phone>415-221-4810</phone>
    <phone_ext>24117</phone_ext>
    <email>Win.Huynh@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Lin, BA</last_name>
      <phone>415-504-2263</phone>
      <email>Bandlab@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Win Huynh, BS</last_name>
      <phone>415-221-4810</phone>
      <phone_ext>23318</phone_ext>
      <email>win.huynh@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Joshua D Woolley, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2014</study_first_submitted>
  <study_first_submitted_qc>November 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2014</study_first_posted>
  <last_update_submitted>May 20, 2016</last_update_submitted>
  <last_update_submitted_qc>May 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Joshua Woolley</investigator_full_name>
    <investigator_title>Assistant Professor in Residence</investigator_title>
  </responsible_party>
  <keyword>oxytocin</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>autism spectrum disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

